Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease
Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
C: Arm Label: Placebo (IP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (IP) | Arm Label: Ustekinumab 1mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 1mg/kg (IP) | Arm Label: Ustekinumab 3 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 3 mg/kg (IP) | Arm Label: Ustekinumab 6 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 6 mg/kg (IP) | Arm Label: Placebo IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Responder - Placebo SC (MP) | Arm Label: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP) | Arm Label: Ustekinumab IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Responder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Placebo (IP); Assigned to Arm(s): Placebo (IP) | Intervention Type: DRUG; Name: Ustekinumab 1mg/kg (IP); Assigned to Arm(s): Ustekinumab 1mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 3 mg/kg (IP); Assigned to Arm(s): Ustekinumab 3 mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 6 mg/kg (IP); Assigned to Arm(s): Ustekinumab 6 mg/kg (IP) | Intervention Type: DRUG; Name: Placebo IV - Responder - Placebo SC (MP); Assigned to Arm(s): Placebo IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP); Assigned to Arm(s): Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
D: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005

Answer: D